The unique granular proteins of eosinophils may have a pathogenetic role in asthma and in the defense against parasitic infestations. However, the mechanisms regulating eosinophil degranulation are largely unknown. We examined the hypothesis that release of these proteins is regulated by endogenous activation of phospholipase A2. Human eosinophils (HE) were isolated from the peripheral blood of 42 subjects either by Percoll density separation or by negative-selection immunomagnetic fractionation. Eosinophil activation was initiated in vitro with 10(-6) M FMLP and 5 micrograms/ml cytochalasin B and was assessed by measurement of eosinophil peroxidase (EPO), leukotriene C4 (LTC4) and superoxide radical (.O2-) secretion. Treatment of HE with 100 microM mepacrine before activation blocked EPO release (2.0 +/-0.2 vs 10.2 +/-2.1% cell content for activated HE, P < 0.004, n = 9), .O2-generation (2.6 +/-0.9 vs 44.2 +/-10.8 nmol/ml per 10(6) HE, P < 0.002, n = 5), and LTC4 secretion (68.2 +/-32.2 vs 1,125.2 +/-526.8 pg/ml per 10(6) HE, P < 0.04, n = 8). Pretreatment of HE with 100 microM 4-bromophenacyl bromide before activation similarly blocked EPO release, .O2-generation and LTC4 secretion. Addition of AA to HE after treatment with 100 microM mepacrine and before subsequent activation reversed the inhibition of both EPO (10.4 +/-2.2% with 1 microM AA vs 2.0 +/-0.2% […] 
Introduction
Human eosinophils may have a prominent role in the defense against parasitic infection and in the alterations ofairway function in asthma (1) . Eosinophil infiltration of airways is a characteristic feature of asthma, and the presence of blood, bronchoalveolar lavage fluid, and tissue eosinophilia correlates to the severity of the disease (2) (3) (4) (5) . Eosinophil activation and secretion of both lipid and protein inflammatory mediators, such as platelet-activating factor (6) , leukotriene C4 (LTC4)' (7, 8) , major basic protein (9, 10) , eosinophil cationic protein (11) , eosinophil-derived neurotoxin (11) , and eosinophil peroxidase (EPO) (11, 12) , have profound effects on the structure and function of airway cells, including the alteration of airway smooth muscle tone and damage to airway epithelial cells. However, the mechanisms by which eosinophils degranulate and release preformed protein mediators into the external environment has not been defined completely.
Phospholipase A2 (EC3.1.1.4, PLA2), a lipolytic enzyme that catalyzes the hydrolysis ofa glycerol phosphatide to yield a lysophosphatide and AA, is an ubiquitous enzyme that exists in both cell membranes (13) and lysosomes (14, 15) . Recently, PLA2 release from eosinophils has been described in association with release of cationic protein granules from eosinophils (16) , suggesting that this enzyme may be a part of either the granular matrix or the membrane ofthe granule. However, the function ofPLA2 in the granule is unknown, and the role ofthis enzyme in the regulation of eosinophil degranulation has not been defined.
The objective ofthis study was to determine ifinhibition of endogenous eosinophil PLA2 alters the release ofgranular protein mediators from activated eosinophils. We used two different inhibitors ofPLA2 function: mepacrine, which forms stable complexes of drug and phospholipid substrate (17, 18) , or 4- bromophenacyl bromide (BPB), which modifies an active site histidine residue in PLA2 (19) . We isolated eosinophils from peripheral blood of normal volunteers and determined EPO release, LTC4 secretion and superoxide radical ('Os) generation after incubation with either mepacrine or BPB. We demonstrate that (a) inhibition of endogenous PLA2 blocks eosinophil degranulation and release of EPO, secretion ofLTC4, generation of *O 2, and (b) addition of exogenous AA, a principal product of the hydrolytic reaction catalyzed by PLA2, reverses the inhibition of eosinophil degranulation and secretion of LTC4, suggesting that both processes may be dependent upon endogenous AA generated by PLA2. These data suggest a mechanism by which products of PLA2 may regulate degranulation and secretion of inflammatory mediators in human eosinophils.
Methods
Isolation ofhuman eosinophils. Human eosinophils were isolated from volunteers according to a protocol approved by the University of Chi-cago Institutional Review Board. Informed consent was obtained from all volunteers in this study before participation. To ensure that the method ofisolation was not a factor in these experiments, two different isolation methods were used.
In the first method, eosinophils were isolated by density fractionation centrifugation (20, 21 ) . Whole blood ( 180 ml) was withdrawn from the antecubital vein of 17 human volunteers and placed into containers containing 2 ml of 1: 1,000 heparin. Blood then was mixed 5:1 with 4.5% dextran in 0.9% NaCl and sedimented for 45 min at 220C. The white blood cell layer was collected, divided into 30-ml aliquots, and layered over 10 ml Ficoll-Hypaque (density 1.077 g/ml) in 50-ml tubes. Cells then were centrifuged at 400 g for 20 min (all centrifugations done at 220C). The pellet containing leukocytes was resuspended in Ca2+-free HBSS and twice washed and centrifugated at 400 g for 10 min. Cells then were suspended in HBSS containing 1 mmol/liter Ca2' and 5% FCS and diluted to a concentration of 2 x 107/ml. In separate 15-ml tubes discontinuous Percoll gradients were prepared (from top to bottom in g/ml [ [1.5] , prepared in HBSS), over which 2 ml of cell suspension was layered. Gradients then were centrifuged at 700 g for 20 min. The interface containing eosinophils ( 1.095-1. 100 g/ml) was collected, diluted in 0.1% gelatin in HBSS containing 1 mmol/liter Ca2+ (GEL) and then centrifuged at 400 g for 10 min. Eosinophils then were washed, centrifugated at 400 g for 10 min and resuspended in GEL. Eosinophils were counted and assessed for purity by Wright stain. Eosinophils were kept on ice until use and used within 1 h of final purification to prevent deterioration.
In the second method, eosinophils were isolated by negative-selection immunomagnetic fractionation using an antibody to CD16, a FcR111 receptor found on neutrophils but not eosinophils (22). In 22 additional human volunteers, 60-120 ml whole blood was withdrawn from the antecubital vein and placed into containers containing 2 ml of 1:1,000 heparin. Blood was diluted 1:1 with Ca2+-free HBSS, layered over 15 ml of 1.083 g/ml Percoll and centrifugated for 30 min at 900 g (all centrifugations done at 4°C). Cells then were diluted 1:4 with an erythrocyte-lysing solution containing 155 mM NH4Cl, 10 mM KHCO, and 0.1 mM EDTA for 15 min. The remaining granulocytes were centrifugated for 10 min at 400 g and resuspended in 25 ,u of 2% FCS in Ca2" -free HBSS; 75 ,ul ofanti-human CD-16 monoclonal antibody bound to 0. l-,m magnetic beads (Miltenyi Biotec GmbH, Bergisch-Gladbach, Federal Republic ofGermany) then was added. Granulocytes were incubated at 4°C for 45 min and then resuspended in 4 ml of 2% FCS in Ca2+-free HBSS. Granulocytes then were passed through a 1 X 10 cm column packed with steel wool and held within a 0.6 Tesla MACS magnet (Becton Dickinson, Mountain View, CA) over 30 min. Neutrophils binding the antibody-magnetic bead were retained in the magnetized steel wool, while eosinophils passing through the column were collected, washed, and resuspended in GEL. Counts and purity were assessed as above. Cells were kept on ice until use and used within 1 h of final purification as above.
Determination of eosinophil peroxidase concentrations in eosinophils and eosinophil-conditioned media. The EPO concentration in cells and conditioned media was measured as the velocity of maximal reaction of oxidation of o-phenylenediamine using a kinetic assay that we have developed previously for these studies (20) . Eosinophil cell suspensions, eosinophil-conditioned medium, and purified EPO (mol wt -70,000) were suspended in GEL and frozen at -70°C until immediately before use. For the assay, 50 I ofsample or EPO standard were combined with 75 ,u of substrate (final concentrations: 0.01% hydrogen peroxide, 6 mM o-phenylenediamine, and 0.06% Triton X-100 dissolved in 60 mM Tris, pH 8.0) in a polystyrene 96-well microplate and placed into a thermoregulating microplate absorbance spectrophotometer (Thermomax; Molecular Devices Corp., Menlo Park, CA) at 37°C. Absorbance at 492 nm was measured every 6 s for 3 min; the maximal velocity of the reaction was calculated by interpolation between successive three points ( 18 s) using customized software (Softmax v2.0 1; Molecular Devices Corp.) on a Macintosh computer, and compared to EPO standards generated at the same time. Standards were assayed in triplicate; suspended cell and conditioned media samples were assayed in duplicate. Eosinophil cell suspensions were diluted 1:4 with HBSS containing 1 mmol/liter Ca2+ immediately before assay. Final EPO concentrations then were calculated from standard curves fitted by four-parameter (iterative log-logit) analysis, and expressed finally as percent total EPO content of the eosinophils (medium/[medium + cell pellet]) in conditioned media (20) .
Determination of LTC4 concentrations in eosinophil-conditioned media by enzyme-linked immunosorbent assay. This technique offers exceptional sensitivity (< 20 pg/ml at 80% B/Bo) and specificity (46% cross-reactivity with leukotriene D4 and < 2% cross-reactivity for other leukotrienes) in biologic fluids. This assay is particularly suitable for these studies because eosinophils do not synthesize leukotriene D4 (23, 24) . Microplates were prepared by coating with mouse monoclonal anti-rabbit IgG (Cayman Chemical Co. Inc., Ann Arbor, MI) in phosphate buffer and incubated for 18 h at 200C. Plates then were saturated with buffer ( 300 mg/liter sodium azide and 3 g/liter BSA in phosphate buffer) for 18 h at 40C. 50 Ml ofeither standard or sample was added to each well, followed by 50 pi ofLTC4-specific acetylcholinesterase tracer and 50 ,l ofanti-LTC4 rabbit antiserum. Plates were incubated for 18 h at 220C, rinsed with buffer five to six times, and developed with 200 ;1 Ellman's reagent (14.6 mM NaCl, 12.5 mM K2HPO4, 0.5 mM acetylthiocholine, and 300 mg/liter 5,5'-dithio-bis-[2-nitrobenzoic acid] in H20 at pH 7.4) as substrate. Absorbance was measured with a microplate spectrophotometer at 412 nm and compared to a standard curve generated at the same time on the same plate. All measurements were made in duplicate.
Determination ofeosinophil viability after inhibition ofphospholipase A2 with mepacrine or BPB. To determine if either mepacrine or BPB decreased eosinophil viability, trypan blue exclusion was determined in eosinophils incubated with either inhibitor. Aliquots of I05 eosinophils isolated by immunomagnetic fractionation were incubated for 30 min at 370C in microfuge tubes containing 0, 1, 3, 10, 30, 100, or 300 ,gM mepacrine (n = 5, isolated by percoll separation) or BPB (n = 3, isolated by magnetic fractionation) in GEL. Eosinophils then were centrifugated at 400 g and pellets were resuspended in 200 al GEL. An equal volume of 0.01% trypan blue was added, and viable eosinophils were counted in a hemacytometer.
Determination ofeosinophil release ofEPO after inhibition ofphospholipase A2. In these experiments, EPO secretion in stimulated eosinophils after PLA2 inhibition was measured. Aliquots of 5 x I05 eosinophils isolated by percoll separation from 11 donors were incubated in separate microfuge tubes containing 3, 10, 30, 100, or 300 MM mepacrine, or 1, 3, 10, 30, 100, or 300MgM BPB, in GEL for 30 min at 370C. Eosinophils then were activated with 10-6 M FMLP plus 5 ;lg/ml cytochalasin B (CYB) (final volume 200 ul) for 30 min at 370C and then centrifugated at 4VC at 400 g. Eosinophil pellets diluted to 1 ml with GEL and conditioned medium (undiluted) were stored separately at -70'C for determination of EPO concentrations. Separate control experiments were performed in the same manner for each experiment, in which eosinophils were pretreated with either 100I M mepacrine or 300 AM BPB but not activated, or activated with FMLP and CYB but not pretreated with either PLA2 antagonist.
Determination ofeosinophilSO2 generation after inhibition ofphospholipaseA2. In these experiments, *O generation in stimulated eosinophils after PLA2 inhibition was measured. The method of Pick and Mizel (25) as modified by Sedgwick et al. Eosinophils were separated by immunomagnetic fractionation for (C) (n = 8), and both Percoll density separation and immunomagnetic fractionation for(A)(n = 11 and 8, respectively) and (B) (n = 5 and 7, respectively). *P < 0.04; §P < 0.02; *P tivated < 0.005; tP < 0.002 vs control.
Reversal of mepacrine-induced inhibition of EPO release, LTC4 secretion and GOT generation by arachidonic acid. To determine the specificity of mepacrine in inhibiting eosinophil activation and degranulation, EPO release and LTC4 secretion were measured in activated eosinophils after incubation with AA. In 13 additional experiments, aliquots of 5 X I05 eosinophils isolated by immunomagnetic fractionation were incubated for 15 min at 370C with 100 MM mepacrine and then for an additional 15 min at 370C with either 1 or 10 MM AA in GEL. Eosinophils then were incubated for 30 min at 370C with 10-6 M FMLP plus 5 ug/iml CYB (final volume 300 Ad). Eosinophils were centrifugated at 400 g for 10 min at 4VC, and both media and cell pellets were stored at -70'C for analysis ofeither EPO (n = five experiments) or LTC4 (n = eight experiments) concentrations. Control experiments with either no mepacrine, no AA, or neither agent were done at the same time using identical numbers of eosinophils.
In three additional experiments the potential ability of AA to reverse the inhibition ofO generation by mepacrine was tested. Eosinophils isolated by immunomagnetic fractionation were incubated in 100 (Fig. 1 ) . Treatment with 5 ,ug/ml CYB alone in three additional experiments did not cause either secretion of EPO (Fig. 2) or generation ofO (data not shown). Treatment with 10-6 M FMLP alone in these experiments also did not cause eosinophil degranulation and release of EPO (Fig. 2) .
There were no differences in the release of EPO in FMLPactivated eosinophils isolated by immunomagnetic fractionation compared to eosinophils isolated by Percoll density centrifugation. EPO 2 .0±0.2% of total cell content (P < 0.004, n = nine experiments, Fig. 3 ). Pretreatment with 100 ,uM BPB decreased subsequent eosinophil release ofEPO from 9.4±2.6% to 2.5±0.8% of total cell content (P < 0.04, n = seven experiments, Fig. 4 ). Inhibition of eosinophil degranulation was caused by preincubation with 2 3 ,uM of either antagonist (Figs. 3 and 4) .
Incubation of nonactivated eosinophils with either mepacrine or BPB did not alter the baseline release of EPO 44 .2±10.8 nmol/ml per 106 eosinophils for activated eosinophils not treated with mepacrine (P < 0.002) (Fig. 5) . Superoxide radical generation was inhibited in eosinophils after incubation with all concentrations ofmepacrine 2 1 AM (Fig. 5) made at 100 pM mepacrine, the point of maximal inhibition, in these and all subsequent experiments (see below). Eosinophils were separated by percoll density gradients. Mepacrine (kuM) Reversal of mepacrine-induced inhibition ofEPO release, LTC4 secretion, and O7 generation by arachidonic acid. To determine the specificity of mepacrine in inhibiting eosinophil degranulation and leukotriene production, experiments were performed measuring EPO release, LTC4 secretion, and 0-2 generation in activated eosinophils after treatment with exogenous AA. Eosinophils in these experiments were isolated by immunomagnetic separation.
Treatment of eosinophils with AA reversed substantially the inhibitory effects of mepacrine on both degranulation and secretion of LTC4. In five experiments, eosinophils treated with both 100 MM mepacrine and 1 uM AA and then activated with FMLP and CYB released EPO at a concentration 10.4±2.2% total cell content vs 4.1±0.8% total cell content for eosinophils treated with mepacrine but not AA (P < 0.02) (Fig.  7) . Treatment with AA did not alter subsequent EPO secretion caused by FMLP and CYB: EPO secretion after both AA and FMLP/CYB was 93.9±21.0% of secretion caused by FMLP/ CYB alone (P = NS). Treatment with AA did not alter EPO release in nonactivated, quiescent eosinophils or cells treated with mepacrine (Table I) .
In eight additional experiments, activation of eosinophils with FMLP + CYB caused LTC4 secretion of 1,125±527 pg/ ml per 106 eosinophils after 30 min, vs 44.2±24.0 pg/ml per 106 eosinophils after 30 min for nonactivated eosinophils (P < 0.04) (Fig. 1) . Incubation with 100 uM mepacrine before activation with FMLP + CYB almost completely inhibited LTC4 secretion (68.2±32.2 vs 1,125±527 pg/ml per 106 eosinophils, P < 0.04) (Fig. 8) . In eosinophils treated with 100 ,M mepacrine, incubation with 10 MM AA before activation with FMLP + CYB restored LTC4 secretion to 695±413 pg/ml per 106 eosinophils (P < 0.04 vs activated eosinophils treated with mepacrine but not AA; P = NS vs activated eosinophils not treated with mepacrine) (Fig. 8) . Treatment with AA did not alter LTC4 secretion in nonactivated, quiescent eosinophils or cells treated with mepacrine (Table I) the concentration ofthe PLA2 inhibitor. In these studies, inhibition of both EPO release and LTC4 secretion was reversed by addition of arachidonic acid. We demonstrate that endogenous PLA2 may regulate mediator secretion and degranulation in eosinophils. Eosinophil activation and degranulation may be caused by a number of agents, such as platelet-activating factor, FMLP, and secretory immunoglobulin A (29) (30) (31) . In these experiments, we used FMLP plus CYB as an activator for eosinophil degranulation. FMLP activates eosinophils by binding to specific membrane receptors (30) , an action which is augmented substantially in the presence of CYB (20, 21) . We have demonstrated previously that FMLP plus CYB causes eosinophil release of EPO that is measured readily in biologic fluids (20) . Eosinophil peroxidase release and LTC4 secretion were readily elicited by FMLP plus CYB in our experiments (Fig. 1 ) . Superoxide radical generation was less readily elicited in eosinophils isolated by immunomagnetic separation compared to Percoll separation (Fig. 1) . In several experiments using eosinophils isolated by immunomagnetic separation, *O2 generation was not substantially above baseline, and these experiments were excluded from analysis. Sufficient O2 was generated after eosinophil activation with FMLP and CYB in each series of experiments to determine the effects of both mepacrine and BPB (Figs. 5 and 6) , and the effects of exogenous AA on inhibition elicited by mepacrine (see above).
Both mepacrine and BPB inhibited subsequent degranulation and 0 2 generation by activated eosinophils, and mepacrine inhibited subsequent LTC4 secretion. Each antagonist inhibits PLA2 by a distinct mechanism. Mepacrine inhibits PLA2 competitively either by direct interaction ( 17) or by formation of stable complexes of drug and phospholipid substrate ( 18 (39) . In the present study, while both EPO release and LTC4 secretion could be restored by addition of exogenous AA, inhibition ofO 2genera-tion by mepacrine was not reversed by exogenous AA. These data suggest that eicosanoid production in eosinophils, as in neutrophils, depends upon activation of PLA2. Our data suggest further that in eosinophils, unlike neutrophils, O2 generation in eosinophils may not be linked to AA metabolism; however, we do not consider our data to be conclusive on this point.
Eosinophil peroxidase is a constituent of the matrix of cationic eosinophil granules (1, 27) . This protein is synthesized during eosinopoiesis and are not further synthesized after release of the cell from the bone marrow (40, 41) . Release of EPO and other eosinophil granular proteins involves solubilization of granular proteins into vacuoles followed by extrusion of the vacoular contents from the eosinophil into the surrounding environment (42) . Therefore, determination of EPO concentrations in eosinophil-conditioned media is a marker for degranulation (20, 43) . Eosinophil degranulation, and the inhibition of degranulation by mepacrine and BPB, were demonstrated consistently by this assay (Figs. 1, 3, 4, and 7) .
In these studies, eosinophils were isolated in these experiments either by separation through discontinuous Percoll density gradients or by negative-selection immunomagnetic bead fractionation. The later method has been developed recently (22) and isolates eosinophils in greater number from equivalent volumes of blood compared with density gradient methods. Each method isolated eosinophils in sufficient purity (>92 and> 98%, respectively) to exclude substantial numbers of neutrophils. In these studies, both the purity of isolated cells and subsequent EPO release after incubation with FMLP + CYB by either method were comparable. Phospholipase A2 can mediate a variety of actions within cells either directly or via subsequent transformation ofits products: arachidonic acid metabolized into prostaglandins, leukotrienes, thromboxanes, and lipoxins; and lysophospholipids metabolized into platelet activating factor (44) . Each of these lipid mediators has been implicated in a number of inflammatory processes and tissue injury, and many may have roles as second messenger (45) . Phospholipase A2 activation also can modify cell membrane dynamics. Phospholipid turnover in cell membranes may represent both replacement of oxidized phospholipids (46) and also reflect fundamental signalling mechanisms by which a cell respond to its environment (44, 45) . We did not delineate which ofthese activities ofPLA2 was responsible for eosinophil degranulation and *02 generation.
In summary, we demonstrate that inhibition ofendogenous eosinophil PLA2 inhibits release of EPO, LTC4 secretion, and *02 generation from isolated, human eosinophils. Inhibition is specific to a product of the hydrolytic reaction catalyzed by PLA2 and can be reversed by addition of exogenous arachidonic acid. These data demonstrate the potential of PLA2 to regulate eosinophil secretory activity that pertains to inflammatory states such as human asthma.
